COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage is available here.

Researchers from Icahn School of Medicine at Mount Sinai was recently awarded a U54 grant ($3.9 million over the first two years as a part of a five-year research proposal) to establish a NCI/SeroNet Center for Serological Excellence at Mount Sinai with a focus on lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login